{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:15:59Z","timestamp":1783041359095,"version":"3.54.6"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To examine and compare human epidermal growth factor receptor 2 (HER2) amplification status in high-grade urothelial carcinoma (HGUCa), using both 2013 and 2018 HER2 reporting guidelines for breast carcinoma from the American Society of Clinical Oncology (ASCO)\/College of American Pathologists (CAP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>HER2 status by fluorescence in situ hybridization (FISH) assay in 78 cases of HGUCa was compared using 2013 and 2018 HER2 reporting guidelines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>HER2 amplification was observed in 22 (28.2%) of 78 tumors, of which 17 were in group 1, 1 in group 2, and 2 each in groups 3 and 4 (FISH assay, 2018). The remaining 14 HER2-amplified tumors (FISH assay, 2013) became negative, falling into group 2 (FISH assay, 2018) and were either negative or equivocal on immunohistochemistry (IHC, 2018). All FISH-negative tumors (n\u2005=\u200537) using 2013 criteria remained negative (group 5, 2018). FISH-equivocal tumors (2013) were further categorized into HER2 amplified (n\u2005=\u20051) and HER2 negative (n\u2005=\u20054) (2018). Overall, 20 (25.6%) tumors had discordant HER2 FISH results (2018 vs 2013).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Implementing 2018 guidelines, HER2 amplification decreased from 36 to 22 cases. The group with a HER2\/CEP17 ratio of 2 or more and average HER2 copy number less than 4 (group 2) were predominantly negative by IHC, suggesting a biologically distinct group of HGUCa that is different from HER2-amplified tumors, which may not respond to HER2-targeted therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqab083","type":"journal-article","created":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T11:31:15Z","timestamp":1618054275000},"page":"1130-1141","source":"Crossref","is-referenced-by-count":10,"title":["Reappraisal of <i>HER2<\/i> Amplification in High-Grade Urothelial Carcinoma Based on 2018 ASCO\/CAP Clinical Practice Guidelines"],"prefix":"10.1093","volume":"156","author":[{"given":"Sambit K","family":"Mohanty","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Advanced Medical Research Institute , Bhubaneswar , India"},{"name":"Department of Pathology and Laboratory Medicine, CORE Diagnostics , Gurgaon , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourav K","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Advanced Medical Research Institute , Bhubaneswar , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Advanced Medical Research Institute , Bhubaneswar , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, CORE Diagnostics , Gurgaon , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, CORE Diagnostics , Gurgaon , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niharika","family":"Pattnaik","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Advanced Medical Research Institute , Bhubaneswar , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Jaiswal","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Advanced Medical Research Institute , Bhubaneswar , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manas R","family":"Baisakh","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Prolife Diagnostics , Bhubaneswar , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Urology, Advanced Medical Research Institute , Bhubaneswar , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manas R","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Department of Urology, Advanced Medical Research Institute , Bhubaneswar , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapas R","family":"Swain","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Advanced Medical Research Institute , Bhubaneswar , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaliprasad","family":"Satpathy","sequence":"additional","affiliation":[{"name":"Department of Urology, Kalinga Hospital , Bhubaneswar , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-1460","authenticated-orcid":false,"given":"Sean R","family":"Williamson","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cleveland Clinic , Cleveland, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil V","family":"Parwani","sequence":"additional","affiliation":[{"name":"Department of Pathology, Wexner Medical Center, Ohio State University , Columbus, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"key":"2023020912514682800_CIT0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2015.01.001","article-title":"Receptor tyrosine kinases: characterisation, mechanism of action and therapeutic interests for bone cancers","volume":"4","author":"S\u00e9galiny","year":"2015","journal-title":"J Bone Oncol."},{"key":"2023020912514682800_CIT0002","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMcibr1909386","article-title":"HER2 and breast cancer\u2014a phenomenal success story","volume":"381","author":"Fayes","year":"2019","journal-title":"N Engl J Med"},{"key":"2023020912514682800_CIT0003","doi-asserted-by":"crossref","first-page":"852748","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int."},{"key":"2023020912514682800_CIT0004","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","article-title":"HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation","volume":"2","author":"Takezawa","year":"2012","journal-title":"Cancer Discov."},{"key":"2023020912514682800_CIT0005","doi-asserted-by":"crossref","first-page":"170007","DOI":"10.1183\/16000617.0007-2017","article-title":"Non-small cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens","volume":"26","author":"Bubendorf","year":"2017","journal-title":"Eur Respir Rev."},{"key":"2023020912514682800_CIT0006","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1158\/2159-8290.CD-15-0730","article-title":"ERBB2 emerges as a new target for colorectal cancer","volume":"5","author":"Pectasides","year":"2015","journal-title":"Cancer Discov."},{"key":"2023020912514682800_CIT0007","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1309\/41VLTFX3YPP1HF6F","article-title":"HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases","volume":"130","author":"Hansel","year":"2008","journal-title":"Am J Clin Pathol."},{"key":"2023020912514682800_CIT0008","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature."},{"key":"2023020912514682800_CIT0009","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/annonc\/mdp488","article-title":"Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients","volume":"21","author":"La\u00e9","year":"2010","journal-title":"Ann Oncol."},{"key":"2023020912514682800_CIT0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med."},{"key":"2023020912514682800_CIT0011","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3346\/jkms.2015.30.8.1068","article-title":"Clinical significance of substaging and HER2 expression in papillary nonmuscle invasive urothelial cancers of the urinary bladder","volume":"30","author":"Lim","year":"2015","journal-title":"J Korean Med Sci."},{"key":"2023020912514682800_CIT0012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12907-017-0046-z","article-title":"Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma","volume":"17","author":"El Ochi","year":"2017","journal-title":"BMC Clin Pathol."},{"key":"2023020912514682800_CIT0013","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.anndiagpath.2019.01.002","article-title":"Fatty acid synthase, HER2\/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer","volume":"39","author":"Abdelrahman","year":"2019","journal-title":"Ann Diagn Pathol"},{"key":"2023020912514682800_CIT0014","first-page":"4935","article-title":"Critical overview of HER2 assessment in bladder cancer: what is missing for a better therapeutic approach?","volume":"37","author":"Cimpean","year":"2017","journal-title":"Anticancer Res."},{"key":"2023020912514682800_CIT0015","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/s41379-018-0023-9","article-title":"Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility","volume":"31","author":"Moktefi","year":"2018","journal-title":"Mod Pathol."},{"key":"2023020912514682800_CIT0016","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1016\/j.clgc.2019.04.011","article-title":"A simple immunohistochemical panel could predict and correlate to clinicopathologic and molecular subgroups of urinary bladder urothelial carcinoma","volume":"17","author":"Makboul","year":"2019","journal-title":"Clin Genitourin Cancer."},{"key":"2023020912514682800_CIT0017","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ajpath.2013.05.013","article-title":"Toward a molecular pathologic classification of urothelial carcinoma","volume":"183","author":"Sj\u00f6dahl","year":"2013","journal-title":"Am J Pathol."},{"key":"2023020912514682800_CIT0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/BLC-180196","article-title":"Systematic review: targeting HER2 in bladder cancer","volume":"5","author":"Koshkin","year":"2019","journal-title":"BLC"},{"key":"2023020912514682800_CIT0019","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ijrobp.2016.12.018","article-title":"A phase 1\/2 trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation after transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer (trial NRG oncology RTOG 0524)","volume":"97","author":"Michaelson","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2023020912514682800_CIT0020","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO.2006.08.0994","article-title":"Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2\/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial","volume":"25","author":"Hussain","year":"2007","journal-title":"J Clin Oncol."},{"key":"2023020912514682800_CIT0021","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2014.10.009","article-title":"Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2","volume":"51","author":"Oudard","year":"2015","journal-title":"Eur J Cancer."},{"key":"2023020912514682800_CIT0022","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.2015.66.3468","article-title":"Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1\/2-positive metastatic bladder cancer","volume":"35","author":"Powles","year":"2017","journal-title":"J Clin Oncol."},{"key":"2023020912514682800_CIT0023","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2015.66.3047","article-title":"Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations","volume":"34","author":"Choudhury","year":"2016","journal-title":"J Clin Oncol."},{"key":"2023020912514682800_CIT0024","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature."},{"key":"2023020912514682800_CIT0025","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.19.01455","article-title":"NSABP B-47\/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2","volume":"38","author":"Fehrenbacher","year":"2020","journal-title":"J Clin Oncol."},{"key":"2023020912514682800_CIT0026","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol."},{"key":"2023020912514682800_CIT0027","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol."},{"key":"2023020912514682800_CIT0028","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol."},{"key":"2023020912514682800_CIT0029","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10549-019-05148-5","article-title":"Impact of the updated 2018 ASCO\/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 FISH results of 2233 cases","volume":"175","author":"Liu","year":"2019","journal-title":"Breast Cancer Res Treat."},{"key":"2023020912514682800_CIT0030","doi-asserted-by":"crossref","first-page":"16726","DOI":"10.1038\/s41598-019-53003-w","article-title":"Impact of the 2018 ASCO\/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep."},{"key":"2023020912514682800_CIT0031","doi-asserted-by":"crossref","first-page":"597","DOI":"10.5858\/arpa.2019-0307-OA","article-title":"Impact of the 2018 American Society of Clinical Oncology\/College of American Pathologists HER2 guideline updates on HER2 assessment in breast cancer with equivocal HER2 immunohistochemistry results with focus on cases with HER2\/CEP17 ratio &lt;2.0 and average HER2 copy number \u22654.0 and &lt;6.0","volume":"144","author":"Hoda","year":"2020","journal-title":"Arch Pathol Lab Med."},{"key":"2023020912514682800_CIT0032","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2016.66.6693","article-title":"HER2 gene amplification testing by fluorescent in situ hybridization (FISH): comparison of the ASCO\u2013College of American Pathologists Guidelines with FISH scores used for enrollment in Breast Cancer International Research Group Clinical Trials","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol."},{"key":"2023020912514682800_CIT0033","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2015.61.8983","article-title":"Change in pattern of HER2 fluorescent in situ hybridization (FISH) results in breast cancers submitted for FISH testing: experience of a reference laboratory using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines","volume":"34","author":"Shah","year":"2016","journal-title":"J Clin Oncol."},{"key":"2023020912514682800_CIT0034","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.5858\/arpa.2016-0009-OA","article-title":"Assessing the New American Society of Clinical Oncology\/College of American Pathologists Guidelines for HER2 testing by fluorescence in situ hybridization: experience of an academic consultation practice","volume":"140","author":"Press","year":"2016","journal-title":"Arch Pathol Lab Med."},{"key":"2023020912514682800_CIT0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/modpathol.2016.175","article-title":"\u201cNon-classical\u201d HER2 FISH results in breast cancer: a multi-institutional study","volume":"30","author":"Ballard","year":"2017","journal-title":"Mod Pathol."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/156\/6\/1130\/49137522\/aqab083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/156\/6\/1130\/49137522\/aqab083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T14:40:59Z","timestamp":1675953659000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/156\/6\/1130\/6298214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,14]]},"published-print":{"date-parts":[[2021,11,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqab083","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,6,14]]}}}